NCT05932173 2023-07-11
A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase 1/2 Unknown
Clinical Trials
27 trialsNCT04265963 2023-04-18
CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04271410 2023-04-18
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04271800 2023-04-18
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04272125 2023-04-18
Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT05672420 2023-01-05
Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2 Unknown
NCT03825367 2022-10-12
Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Unknown
NCT04632316 2022-06-21
A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia
Glycostem Therapeutics BV
Phase 1/2 Unknown
NCT05309213 2022-04-04
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1/2 Unknown
NCT05164042 2021-12-20
CAR-T
Shenzhen University General Hospital
Phase 1/2 Unknown
NCT05061147 2021-10-01
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Maxinovel Pty., Ltd.
Phase 1/2 Unknown
NCT03262298 2021-02-09
Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies
Affiliated Hospital to Academy of Military Medical Sciences
Phase 1/2 Unknown
NCT04163575 2019-12-23
Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL
Kecellitics Biotech Company Ltd
Phase 1/2 Unknown
NCT02349698 2019-06-25
A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
Southwest Hospital, China
Phase 1/2 Unknown
NCT02935153 2019-06-25
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
Southwest Hospital, China
Phase 1/2 Unknown
NCT02937103 2019-06-25
A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies
Southwest Hospital, China
Phase 1/2 Unknown
NCT02954445 2019-06-25
A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies
Southwest Hospital, China
Phase 1/2 Unknown
NCT02958410 2019-06-25
A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies
Southwest Hospital, China
Phase 1/2 Unknown
NCT03312205 2019-01-09
CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
Hebei Senlang Biotechnology Inc., Ltd.
Phase 1/2 Unknown
NCT03142646 2018-05-01
IM19CAR-T
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1/2 Unknown
NCT02568241 2016-09-29
IDPR-HSCT
Peking University People's Hospital
Phase 1/2 Unknown
NCT02672501 2016-02-03
A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia
Shanghai GeneChem Co., Ltd.
Phase 1/2 Unknown
NCT00679536 2014-01-23
Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors
Ann & Robert H Lurie Children's Hospital of Chicago
Phase 1/2 Unknown
NCT01983761 2013-11-18
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
Targazyme, Inc.
Phase 1/2 Unknown
NCT00028847 2013-09-17
Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT01728389 2013-07-24
Intrabone Transplantation of Allogenic Peripheral Blood Stem Cells in Patients With Myeloid and Lymphoid Malignancies.
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 1/2 Unknown
NCT00838240 2012-07-20
AML-14A
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1/2 Unknown